NEW YORK, NY--(Marketwire -06/21/12)- Despite the recent economic turmoil in Europe, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 28 percent and 34 percent, respectively. As the world continues to face evolving health challenges the discoveries of new therapeutics and vaccines are critical. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Genetic Technologies Ltd. (GENE) and MannKind Corporation (MNKD).
Access to the full company reports can be found at:
Expiring patents have been a major dilemma for pharmaceutical companies. New products that are being introduced are not expected to generate the same level of revenues of the products that have lost patent protection. In the last decade the Pharmaceutical Industry has spent $1.1 trillion on research and development as companies scramble to replace lost revenues from patent expirations. Mergers & Acquisitions activity is expected to pick up in 2012 as companies look to make up for loss revenues. M&A allow companies to acquire products that are already proven in the market place without the hassle and costs associated with research and development.
"Many of the pharmaceutical companies started producing everything in-house out of their own R&D organizations and over time they've failed to produce enough that way. So the industry is now coalescing around a 50-50 model of half on your own and half bought in. There are some things we'll do for ourselves but we need to be constantly on the lookout for new technologies," said Angus Russell, Chief Executive of Shire PLC.
Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Genetic Technologies is a genetic testing laboratory based in Melbourne, Australia. In June 2011, GENE launched BREVAGen in the U.S. for assessing a woman's risk of developing breast cancer based on clinical characteristics and analysis of a panel of somatic mutations. The company also derives significant revenue from licensing of patents and other intellectual property pertaining to the role of non-coding DNA and related applications for diagnostic testing. Shares have surged over 75 percent in the last month after the company released a positive update on its breast cancer test BREVAGen.
MannKind focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. The company is currently recruiting adult patients with type 1 or type 2 diabetes for two new clinical trials. Shares of the company have rallied 17.5 percent in the last month.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: